Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns
Cancer treatment has entered the era of precision medicine, where knowledge of a patient's genetic profile is used to facilitate early diagnosis, drug selection, prognosis, prediction of drug responsiveness, the onset of secondary resistance, and relapse. Circulating free DNA (cfDNA) has emerge...
Guardado en:
Autores principales: | Jun-Liang Lu, Zhi-Yong Liang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
KeAi Communications Co., Ltd.
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f443e279774f4ecf8cda2b1b13aa8425 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Circulating tumor cells: quintessential precision oncology presenting challenges for biology
por: Rebecca J. Morris
Publicado: (2017) - JCO Precision Oncology
-
Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology
por: Ashish Manne, et al.
Publicado: (2021) -
Microscaled proteogenomic methods for precision oncology
por: Shankha Satpathy, et al.
Publicado: (2020) -
Evaluation of pre-analytical factors affecting plasma DNA analysis
por: Havell Markus, et al.
Publicado: (2018)